
News|Articles|November 1, 2002
From the ESC Congress: Combination therapy improves LV remodeling in CHF better than monotherapy
Patients with mild chronic heart failure who are treated early on with the beta blocker carvedilol (Coreg) along with the angiotensin-converting enzyme (ACE) inhibitor enalapril demonstrated a significantly greater improvement in left ventricular remodeling than patients receiving either drug alone, according to a 572-patient study presented at the European Society of Cardiology (ESC) Congress in September in Berlin. The results reinforce current treatment recommendations.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sponsored: The Teva Biosimilars Trend Report
2
Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds
3
FDA Accepts NDA for Investigational Maintenance Asthma Treatment
4
The 6-Year Cure Threshold: Redefining Cure for Colon Cancer Survivors
5